Arabic Arabic English English French French German German
dark

Allogene’s AlloCAR T Trials are Full Speed Ahead as FDA Lifts Hold

​Allogene announced that the chromosomal abnormality was not detected in any manufactured AlloCAR T product or any patient treated with the same lot of drugs.  Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Sanofi, Exscientia Expand in AI with Up-to-$5.2B Cancer, Immunology Alliance

Next Post

Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients

Related Posts
Total
0
Share